Page last updated: 2024-12-06

dauricine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dauricine is a naturally occurring aporphine alkaloid isolated from the root bark of the plant *Menispermum dauricum*. It exhibits a wide range of pharmacological activities, including anti-inflammatory, anti-cancer, and anti-depressant effects. Dauricine has been shown to inhibit the production of pro-inflammatory cytokines and to induce apoptosis in cancer cells. Its anti-depressant effects are attributed to its ability to inhibit the reuptake of serotonin and dopamine in the brain. The unique structure and diverse biological activities of dauricine have made it a subject of significant research interest. Studies are ongoing to further explore its therapeutic potential and to develop new drugs based on its structure.'

dauricine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dauricine : A bisbenzylisoquinoline alkaloid resulting from the formal oxidative dimerisation of 4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenol by attachment of the phenolic oxygen of one molecule to the benzene ring of the second (ortho to the phenolic hydroxy group of the latter). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID73400
CHEMBL ID442717
CHEBI ID4331
SCHEMBL ID2233953
MeSH IDM0109796

Synonyms (26)

Synonym
8qto90g5w5 ,
unii-8qto90g5w5
nsc-36413
nsc 36413
phenol, 4-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)-2-(4-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)-, (r-(r*,r*))-
phenol, 4-[[(1r)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl]methyl]-2-[4-[[(1r)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl]methyl]phenoxy]-
4-[[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl]-2-[4-[[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl]phenoxy]phenol
dauricine
C09419
CHEBI:4331 ,
4-{[(1r)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-2-(4-{[(1r)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenoxy)phenol
CHEMBL442717
S9295
bdbm50370415
FT-0624458
4-(((1r)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)-2-(4-(((1r)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)phenol
dauricine [mi]
SCHEMBL2233953
6,6'-di-o-methyldauricoline
AKOS037514611
HY-N0220
Q5228100
A14718
DTXSID90966808
CCG-270271
CS-0008258

Research Excerpts

Overview

Dauricine (Dau) is a natural alkaloid exhibiting anti-proliferative activity against several different types of malignant cell. It is a bisbenzylisoquinoline alkaloids from Stephaia tetrandra.

ExcerptReferenceRelevance
"Dauricine (Dau) is a natural alkaloid exhibiting anti-proliferative activity against several different types of malignant cell. "( Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a:HK2/PKM2 modulation.
Deng, X; Hao, J; Li, W; Qiu, Y; Shu, G; Zhao, C, 2018
)
3.37
"Dauricine is a bisbenzylisoquinoline alkaloid derivative and has shown multiple pharmacological properties. "( Detection of protein adduction derived from dauricine by alkaline permethylation.
Liu, Y; Peng, Y; Xie, H; Zhao, D; Zheng, J, 2016
)
2.14
"Dauricine (Dau) is a bisbenzylisoquinoline alkaloid from Stephaia tetrandra."( Reduction of doxorubicin resistance by tetrandrine and dauricine in harringtonine-resistant human leukemia (HL60) cells.
He, QY; Meng, FH; Zhang, HQ, 1996
)
1.26

Effects

Dauricine has been found that has significant neuroprotective effect on Alzheimer's disease (AD), but the mechanism is unclear. We further investigated the possible mechanism of dauricin on AD.

ExcerptReferenceRelevance
"Dauricine (Dau) has recently received widespread attention due to its multiple targets and low price."( Dauricine regulates prostate cancer progression by inhibiting PI3K/AKT-dependent M2 polarization of macrophages.
Che, N; Jin, Y; Li, M; Liu, X; Xuan, Y, 2023
)
3.07
"Dauricine has been found that has significant neuroprotective effect on Alzheimer's disease (AD), but the mechanism is unclear, so we further investigated the possible mechanism of dauricine on AD."( Antioxidative and antiapoptosis: Neuroprotective effects of dauricine in Alzheimer's disease models.
Chen, W; Deng, L; Li, M; Pu, Z; Wang, K; Wang, L, 2020
)
2.24

Actions

Dauricine (Dau) has the potential to be used as an adjuvant drug against pancreatic cancer. The working mechanism of Dau has not been elucidated. Dau inhibited the increase in [Ca2+]i and decrease in Deltapsim.

ExcerptReferenceRelevance
"Dauricine (Dau) can inhibit the proliferation of the pancreatic cancer cell line, and has the potential to be used as an adjuvant drug against pancreatic cancer; however, the working mechanism of Dau has not been elucidated."( Dauricine inhibits human pancreatic carcinoma cell proliferation through regulating miRNAs.
Bai, Y; Guo, T; Jiang, L; Jiang, Y; Liu, P, 2021
)
2.79
"Dauricine inhibited the increase in [Ca2+]i and decrease in Deltapsim induced by 30 min of hypoxia and hypoglycemia."( Neuroprotective effect of dauricine in cortical neuron culture exposed to hypoxia and hypoglycemia: involvement of correcting perturbed calcium homeostasis.
Gong, PL; Li, YH, 2007
)
1.36

Toxicity

ExcerptReferenceRelevance
" However, the adverse effects and toxicity of the alkaloid are unfortunately ignored."( Pulmonary toxicity and metabolic activation of dauricine in CD-1 mice.
Chen, X; Dai, J; Gu, Y; Jin, H; Liu, J; Zheng, J; Zhong, D, 2010
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic and PK-PD model parameters were calculated."( Pharmacokinetic-pharmacodynamic modeling of daurisoline and dauricine in beagle dogs.
Chen, H; Gu, SF; Shi, SJ; Zeng, FD, 2003
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" Besides, compared to dauricine alone, combined with clindamycin had more remarkably effects on severe pneumonia in vitro."( Dauricine combined with clindamycin inhibits severe pneumonia co-infected by influenza virus H5N1 and Streptococcus pneumoniae in vitro and in vivo through NF-κB signaling pathway.
Chen, X; Li, H; Zhou, SJ, 2018
)
2.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
bisbenzylisoquinoline alkaloidA type of benzylisoquinoline alkaloid whose structures are built up of two benzylisoquinoline units linked by ether bridges. Various structural patterns resulting from additional bridging between the two units by direct carbon-carbon bridging or by methylenedioxy groups are common.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)16.00000.00091.901410.0000AID240820
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID397128Inhibition of formyl-methionyl-leucyl-phenylalanine induced superoxide generation in PMNC
AID1743206Cytotoxicity against human HepG2 cells overexpressing EGFP-CYP3A4 assessed as reduction in cell viability at 15 uM measured after 24 hrs by propidium iodide staining based flow cytometry2020European journal of medicinal chemistry, Dec-01, Volume: 207Synthesis, biological evaluation and toxicity of novel tetrandrine analogues.
AID397138Toxicity in ip dosed rat
AID1663397Inhibition of P-glycoprotein-mediated Rhodamine-123 efflux in human MOLT4/DNR cells assessed as inhibition of P-glycoprotein efflux function at 10 uM incubated for 1 hr by flow cytometry2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (95)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (21.05)18.7374
1990's25 (26.32)18.2507
2000's20 (21.05)29.6817
2010's17 (17.89)24.3611
2020's13 (13.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.40 (24.57)
Research Supply Index4.57 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (5.21%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other91 (94.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]